#### **Investments by Year**






Investment Data - 2024 Q2 | 1


# **Investments by Deal Type** for All Regions





# **Investments by Deal Type for North America**






**Deal Type** 


# **Investments by Deal Type** for Asia Pacific





# **Investments by Deal Type** for Europe






Investment Data - 2024 Q2 | 5

### **Investments by Month**





#### Public Equity 2024 YTD

Investment Data - 2024 Q2 | 6

## **Methodology Notes for Investment Data**



#### Methodology Notes

1. Investment data represent a snapshot in time; this snapshot was taken in July 2024.

2. Investement regions are based on the location of the parent headquarters of a company, whenever known, at the highest definition of 'Parent Company' available.

3. Although parent headquarters reside in a single region, investments may occur across parties in multiple regions, or in regions not listed; the sum of investments across regions will not be equivalent to the total investments.

4. Investments include upfront payments; milestones and final prices (including conversion rates at later dates) are not represented.

5. Investments exclude M&A and grants (e.g., academic, governement, and not-forprofit/NGO/foundation sources and recipients).

6. Public equity is based on earliest weekly available data for indices and individual stocks within the calendar year; earliest available date may vary by exchange.

7. ARM-specific indices are comprised of unweighted averages across individual publicly traded stocks whose primary revenue source is the therapeutic area relevant to each index.